Light-Chain Deposition Diseases of the CNS: Review of Pathogenesis, Imaging Features, and Radiographic Mimics

References

1. 1.↵
   1. Randall RE,
   2. Williamson WC Jr.,
   3. Mullinax F, et al

   . Manifestations of systemic light chain deposition. Am J Med 1976;60:293–99 doi:10.1016/0002-9343(76)90440-x pmid:814812

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Khoor A,
   2. Myers JL,
   3. Tazelaar HD, et al

   . Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol 2004;121:200–04 doi:10.1309/3GEC-PW24-02F6-V8EK pmid:14983932

   CrossRefPubMed
3. 3.↵
   1. Rostagno A,
   2. Frizzera G,
   3. Ylagan L, et al

   . Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits (‘aggregoma’): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. Br J Haematol 2002;119:62–69 doi:10.1046/j.1365-2141.2002.03781.x pmid:12358904

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Rho L,
   2. Qiu L,
   3. Strauchen JA, et al

   . Pulmonary manifestations of light chain deposition disease. Respirology 2009;14:767–70 doi:10.1111/j.1440-1843.2009.01560.x pmid:19659654

   CrossRefPubMed
5. 5.↵
   1. Kijner CH,
   2. Yousem SA

   . Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol 1988;12:405–13 doi:10.1097/00000478-198805000-00009 pmid:3129952

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Grassi MP,
   2. Clerici F,
   3. Perin C, et al

   . Light chain deposition disease neuropathy resembling amyloid neuropathy in a multiple myeloma patient. Ital J Neurol Sci 1998;19:229–33 doi:10.1007/BF02427609 pmid:10933463

   CrossRefPubMed
7. 7.↵
   1. Matjašič A,
   2. Wechtersbach K,
   3. Kavalar R, et al

   . Brain aggregoma with clonal B-cell perivascular proliferation detected by next-generation sequencing. A case report and review of the literature. Folia Neuropathol 2021;59:205–11 doi:10.5114/fn.2021.106405 pmid:34284548

   CrossRefPubMed
8. 8.↵
   1. Popović M,
   2. Tavćar R,
   3. Glavač D, et al

   . Light chain deposition disease restricted to the brain: the first case report. Hum Pathol 2007;38:179–84 doi:10.1016/j.humpath.2006.07.010 pmid:17059841

   CrossRefPubMed
9. 9.↵
   1. Schröder R,
   2. Linke RP

   . Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Virchows Arch 1999;434:551–60 doi:10.1007/s004280050383 pmid:10394892

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Cramer SP,
    2. Simonsen H,
    3. Frederiksen JL, et al

    . Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 2014;4:182–89 doi:10.1016/j.nicl.2013.12.001 pmid:24371801

    CrossRefPubMed
11. 11.↵
    1. Ueno M,
    2. Akiguchi I,
    3. Hosokawa M, et al

    . Blood-brain barrier permeability in the periventricular areas of the normal mouse brain. Acta Neuropathol 2000;99:385–92 doi:10.1007/s004010051140 pmid:10787037

    CrossRefPubMed
12. 12.↵
    1. Mercado JJ,
    2. Markert JM,
    3. Meador W, et al

    . Primary CNS nonamyloidogenic light chain deposition disease: case report and brief review. Int J Surg Pathol 2017;25:755–60 doi:10.1177/1066896917717338 pmid:28669250

    CrossRefPubMed
13. 13.↵
    1. Pantazis G,
    2. Psaras T,
    3. Krope K, et al

    . Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue. Clin Neuropathol 2010;29:378–83 doi:10.5414/npp29378 pmid:21073842

    CrossRefPubMed
14. 14.↵
    1. Boulter TD,
    2. Sadaka A,
    3. Nakawah MO, et al

    . Primary central nervous system lymphoma with light chain deposition disease (aggregoma). J Neuroophthalmol 2018;38:195–97 doi:10.1097/WNO.0000000000000612 pmid:29280764

    CrossRefPubMed
15. 15.↵
    1. Grainger BT,
    2. Issa S,
    3. Anderson NE

    . Primary idiopathic CNS non-amyloidogenic light chain deposition disease complicated by treatment-resistant focal seizure disorder. J Clin Neurosci 2019;59:313–15 doi:10.1016/j.jocn.2018.10.123 pmid:30424969

    CrossRefPubMed
16. 16.↵
    1. Vital A,
    2. Ellie E,
    3. Loiseau H

    . A 61-year-old man with instability of gait and right hand clumsiness. Brain Pathol 2010;20:273–74 doi:10.1111/j.1750-3639.2009.00349.x pmid:20438489

    CrossRefPubMed
17. 17.↵
    1. Yu JPJ,
    2. Wilson DM,
    3. Chang EF, et al

    . Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. Clin Imaging 2014;38:868–71 doi:10.1016/j.clinimag.2014.06.015 pmid:25084689

    CrossRefPubMed
18. 18.↵
    1. Buxbaum JN,
    2. Chuba JV,
    3. Hellman GC, et al

    . Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990;112:455–64 doi:10.7326/0003-4819-76-3-112-6-455 pmid:2106817

    CrossRefPubMedWeb of Science
19. ↵
    1. Gandhi D,
    2. Wee R,
    3. Goyal M

    19. Gandhi D, Wee R, Goyal M. CT and MR imaging of intracerebral amyloidoma: case report and review of the literature. AJNR Am J Neuroradiol 2003;24:519–22 pmid:12637308

    PubMed
20. 20.
    1. Eriksson L,
    2. Sletten K,
    3. Benson L, et al

    . Tumor-like localized amyloid of the brain is derived from immunoglobin light chain. Scand J Immunol 1993;37:623–26 doi:10.1111/j.1365-3083.1993.tb01673.x pmid:8316759

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Lee J,
    2. Krol G,
    3. Rosenblum M

    . Primary amyloidoma of the brain: CT and MR presentation. AJNR Am J Neuroradiol 1995;16:712–14 pmid:7611027

    Abstract/FREE Full Text
22. 22.↵
    1. Caerts B,
    2. Mol V,
    3. Sainte T, et al

    . CT and MRI of amyloidoma of the CNS. Eur Radiology 1997;7:474–76 doi:10.1007/s003300050186 pmid:9204322

    CrossRefPubMed
23. 23.↵
    1. Blattler T,
    2. Siegel AM,
    3. Jochum W, et al

    . Primary cerebral amyloidoma. Neurology 2001;56:777 doi:10.1212/wnl.56.6.777 pmid:11274314

    CrossRefPubMed
24. 24.↵
    1. Abdel Razek AAK,
    2. Alvarez H,
    3. Bagg S, et al

    . Imaging spectrum of CNS vasculitis. RadioGraphics 2014;34:873–94 doi:10.1148/rg.344135028 pmid:25019429

    CrossRefPubMed
25. 25.↵
    1. Dumas JL,
    2. Valeyre D,
    3. Belin C, et al

    . Central nervous system sarcoidosis: follow-up at MRI during steroid therapy. Radiology 2000;214:411–20 doi:10.1148/radiology.214.2.r00fe05411 pmid:10671588

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Urbach H,
    2. Kristof R,
    3. Zentner J, et al

    . Sarcoidosis presenting as an intra- or extra-cranial mass: report of two cases. Neuroradiology 1997;39:516–19 doi:10.1007/s002340050457 pmid:9258931

    CrossRefPubMed
27. 27.↵
    1. Pons-Escoda A,
    2. Naval-Baudin P,
    3. Velasco R, et al

    . Imaging of lymphomas involving the CNS: an update-review of the full spectrum of disease with an emphasis on the World Health Organization classifications of CNS tumors 2021 and hematolymphoid tumors 2022. AJNR Am J Neuroradiol 2023;44:358–66 doi:10.3174/ajnr.A7795 pmid:36822829

    Abstract/FREE Full Text
28. 28.↵
    1. Vuori K,
    2. Kankaanranta L,
    3. Häkkinen AM, et al

    . Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 2004;230:703–08 doi:10.1148/radiol.2303021804 pmid:14739313

    CrossRefPubMed
29. 29.↵
    1. Jimenez-Zepeda VH

    . Light chain deposition disease: novel biological insights and treatment advances. Int J Lab Hematol 2012;34:347–55 doi:10.1111/j.1751-553X.2012.01419.x pmid:22471811

    CrossRefPubMed